Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
Executive Summary
FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events
You may also be interested in...
Opana Withdrawal Request Builds On US FDA Actions On Palladone, OxyContin
Earlier withdrawals of Purdue’s Palladone and original OxyContin create precedent for request that Endo’s Opana ER come off market due to risk of abuse; former chief counsel sees agency's move as ‘tip of the iceberg’ on opioid safety actions.
FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question
Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C
FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question
Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C